RI
ATRA icon

RTW Investments’s Atara Biotherapeutics ATRA Stock Holding History

RTW Investments’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-22,245
Closed -$10.1M – 39
2017
Q4 		$10.1M Sell
22,245
-3,996
-15% -$1.48M 1.68% 19
2017
Q3 		$10.9M Sell
26,241
-20,669
-44% -$7.79M 1.89% 18
2017
Q2 		$16.4M Buy
46,910
+10,561
+29% +$4.07M 3.46% 10
2017
Q1 		$18.7M Buy
36,349
+21,444
+144% +$8.88M 4.92% 8
2016
Q4 		$5.29M Sell
14,905
-3,420
-19% -$1.45M 1.99% 15
2016
Q3 		$9.8M Sell
18,325
-310
-2% -$168K 2.96% 11
2016
Q2 		$10.5M Sell
18,635
-290
-2% -$139K 3.58% 11
2016
Q1 		$9M Buy
18,925
+1,568
+9% +$706K 3.27% 14
2015
Q4 		$11.5M Buy
17,357
+6,837
+65% +$5.17M 3.73% 9
2015
Q3 		$8.27M Buy
+10,520
New +$12.8M 2.57% 13

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments's ATRA Position: Q1 2018 in Review

RTW Investments sold out of Atara Biotherapeutics (ATRA) in Q1 2018, closing a stake of 22,245 shares — an estimated $10.1M sold.

RTW Investments first reported a position in ATRA in Q3 2015 and held it in 10 quarters. The position peaked at $18.7M in Q1 2017. 114 funds tracked by Wall St. Rank hold ATRA as of Q1 2018.

  • RTW Investments reported no remaining Atara Biotherapeutics position as of Q1 2018 after selling out during the quarter.
  • RTW Investments sold 22,245 Atara Biotherapeutics shares in Q1 2018, an estimated $10.1M.
  • RTW Investments first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 10 quarters.
  • RTW Investments's Atara Biotherapeutics position peaked at $18.7M in Q1 2017.
  • 114 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2018.

Based on RTW Investments's 13F filing for Q1 2018, filed 14 May 2018.